{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:27:56Z","timestamp":1793834876458,"version":"4.6.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glial fibrillary acidic protein (GFAP) has been suggested as a biomarker for reactive astrogliosis. We measured the levels of plasma GFAP by Simoa in 60 patients with PD with normal cognition, 63 with mild cognitive impairment (PD-MCI), 24 with dementia (PDD) and 15 healthy controls. A subgroup of patients with PD-MCI (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200931) was followed up for 4.1\u2009\u00b1\u20092.3 years. Compared with healthy controls, plasma GFAP levels were elevated in patients with PDD (adjusted\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and PD-MCI (adjusted\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.013) and were negatively correlated with the Mini Mental State Examination (MMSE) score in PD participants. Plasma GFAP predicted MCI-to-dementia conversion with an AUC of 0.90, higher than NfL, Tau and pTau181. Our results support that plasma GFAP has potential value for distinguishing patients with PDD, and predicting MCI-to-dementia conversion in PD.\n                  <\/jats:p>","DOI":"10.1038\/s41531-023-00447-7","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T11:03:23Z","timestamp":1676027003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Plasma GFAP in Parkinson\u2019s disease with cognitive impairment and its potential to predict conversion to dementia"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2819-6554","authenticated-orcid":false,"given":"Yilin","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoniu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2748-395X","authenticated-orcid":false,"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"447_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M. & Morris, J. G. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov. Disord. 23, 837\u2013844 (2008).","journal-title":"Mov. Disord."},{"key":"447_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","volume":"65","author":"D Muslimovic","year":"2005","unstructured":"Muslimovic, D., Post, B., Speelman, J. D. & Schmand, B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65, 1239\u20131245 (2005).","journal-title":"Neurology"},{"key":"447_CR3","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00401-006-0119-z","volume":"112","author":"E Croisier","year":"2006","unstructured":"Croisier, E. & Graeber, M. B. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol. 112, 517\u2013530 (2006).","journal-title":"Acta Neuropathol."},{"key":"447_CR4","doi-asserted-by":"crossref","unstructured":"Rizor, A., Pajarillo, E., Johnson, J., Aschner, M. & Lee, E. Astrocytic oxidative\/nitrosative stress contributes to parkinson\u2019s disease pathogenesis: the dual role of reactive astrocytes. Antioxidants 8, 265(2019).","DOI":"10.3390\/antiox8080265"},{"key":"447_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","volume":"46","author":"SA Liddelow","year":"2017","unstructured":"Liddelow, S. A. & Barres, B. A. Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957\u2013967 (2017).","journal-title":"Immunity"},{"key":"447_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.clineuro.2011.11.002","volume":"114","author":"W Su","year":"2012","unstructured":"Su, W., Chen, H. B., Li, S. H. & Wu, D. Y. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson\u2019s disease patients. Clin. Neurol. Neurosurg. 114, 372\u2013375 (2012).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"447_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl, P. et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J. Alzheimers Dis. 67, 481\u2013488 (2019).","journal-title":"J. Alzheimers Dis."},{"key":"447_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181\u2013184 (1992).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"447_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"447_CR10","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck, A. T., Steer, R. A., Ball, R. & Ranieri, W. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J. Pers. Assess. 67, 588\u2013597 (1996).","journal-title":"J. Pers. Assess."},{"key":"447_CR11","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson, C. L. et al. Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov. Disord. 25, 2649\u20132653 (2010).","journal-title":"Mov. Disord."},{"key":"447_CR12","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1212\/WNL.0b013e3181c34b47","volume":"73","author":"S Hoops","year":"2009","unstructured":"Hoops, S. et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73, 1738\u20131745 (2009).","journal-title":"Neurology"},{"key":"447_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.acn.2005.07.003","volume":"21","author":"LK Sheridan","year":"2006","unstructured":"Sheridan, L. K. et al. Normative Symbol Digit Modalities Test performance in a community-based sample. Arch. Clin. Neuropsychol. 21, 23\u201328 (2006).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"447_CR14","doi-asserted-by":"publisher","first-page":"e57333","DOI":"10.1371\/journal.pone.0057333","volume":"8","author":"Q Zhao","year":"2013","unstructured":"Zhao, Q. et al. The Shape Trail Test: application of a new variant of the Trail making test. PLoS ONE 8, e57333 (2013).","journal-title":"PLoS ONE"},{"key":"447_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/13854040590945210","volume":"19","author":"BA Steinberg","year":"2005","unstructured":"Steinberg, B. A., Bieliauskas, L. A., Smith, G. E. & Ivnik, R. J. Mayo\u2019s older americans normative studies: age- and IQ-adjusted norms for the trail-making test, the stroop test, and MAE controlled oral word association test. Clin. Neuropsychol. 19, 329\u2013377 (2005).","journal-title":"Clin. Neuropsychol."},{"key":"447_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/13854040590945337","volume":"19","author":"JA Lucas","year":"2005","unstructured":"Lucas, J. A. et al. Mayo\u2019s older african americans normative studies: norms for boston naming test, controlled oral word association, category fluency, animal naming, token test, WRAT-3 reading, trail making test, stroop test, and judgment of line orientation. Clin. Neuropsychol. 19, 243\u2013269 (2005).","journal-title":"Clin. Neuropsychol."},{"key":"447_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/WAD.0b013e3181999e92","volume":"23","author":"Q Guo","year":"2009","unstructured":"Guo, Q., Zhao, Q., Chen, M., Ding, D. & Hong, Z. A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis. Assoc. Disord. 23, 253\u2013259 (2009).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"447_CR18","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s100720200003","volume":"22","author":"P Caffarra","year":"2002","unstructured":"Caffarra, P., Vezzadini, G., Dieci, F., Zonato, F. & Venneri, A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol. Sci. 22, 443\u2013447 (2002).","journal-title":"Neurol. Sci."},{"key":"447_CR19","first-page":"234","volume":"41","author":"Q Guo","year":"2008","unstructured":"Guo, Q., Fu, J., Yuan, J., Zhao, Q. & Hong, Z. A study of validity of a new scoring system of clock drawing test. Chin. J. Neurol. 41, 234\u2013237 (2008).","journal-title":"Chin. J. Neurol."},{"key":"447_CR20","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois, B. et al. Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the movement disorder society task force. Mov. Disord. 22, 2314\u20132324 (2007).","journal-title":"Mov. Disord."},{"key":"447_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.24893","volume":"27","author":"I Litvan","year":"2012","unstructured":"Litvan, I. et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27, 349\u2013356 (2012).","journal-title":"Mov. Disord."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00447-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00447-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T05:52:26Z","timestamp":1725601946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00447-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["447"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00447-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"9 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}